According to Axon Enterprise
's latest financial reports the company has $1.32 B in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | $1.32 B | 35.48% |
2022-12-31 | $0.97 B | 120.01% |
2021-12-31 | $0.44 B | -21.17% |
2020-12-31 | $0.56 B | 60.2% |
2019-12-31 | $0.35 B | 0.38% |
2018-12-31 | $0.34 B | 326.34% |
2017-12-31 | $81.96 M | -7.97% |
2016-12-31 | $89.06 M | -18.87% |
2015-12-31 | $0.10 B | 35.3% |
2014-12-31 | $81.14 M | 57.95% |
2013-12-31 | $51.37 M | 35.88% |
2012-12-31 | $37.8 M | 43.16% |
2011-12-31 | $26.4 M | -38.13% |
2010-12-31 | $42.68 M | -6.2% |
2009-12-31 | $45.5 M | -7.85% |
2008-12-31 | $49.37 M | -3.75% |
2007-12-31 | $51.3 M | 129.73% |
2006-12-31 | $22.33 M | 36.56% |
2005-12-31 | $16.35 M | -48.83% |
2004-12-31 | $31.95 M | 101.27% |
2003-12-31 | $15.87 M | 343.91% |
2002-12-31 | $3.57 M | -36.54% |
2001-12-31 | $5.63 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
XBiotech XBIT | $0.20 B | -84.85% | ๐บ๐ธ USA |
Sangamo Therapeutics
SGMO | $81 M | -93.87% | ๐บ๐ธ USA |
Flexion Therapeutics
FLXN | N/A | N/A | ๐บ๐ธ USA |
Exelixis EXEL | $0.99 B | -24.63% | ๐บ๐ธ USA |